Yahoo Poland Wyszukiwanie w Internecie

Search results

1. www.ncbi.nlm.nih.gov › pmc › articlesBiologic Treatments of Psoriasis: An Update for the Clinician

   www.ncbi.nlm.nih.gov › pmc › articles

   16 lut 2021 · To maintain response to treatment, practitioners can consider increasing the dosing regimen to 80 mg SC every 2 weeks. It is the only biologic with data and FDA labeling specifically for genital plaque psoriasis. Also, ixekizumab is the only IL-17 agent that is FDA approved for treatment of plaque psoriasis down to the age of 6 years old.

2. www.ncbi.nlm.nih.gov › pmc › articlesBiologic Treatment Algorithms for Moderate-to-Severe Psoriasis...

   www.ncbi.nlm.nih.gov › pmc › articles

   16 kwi 2021 · Approved biologics for the treatment of moderate-to-severe psoriasis include tumor necrosis factor inhibitors (TNFi: infliximab, etanercept, adalimumab, certolizumab pegol), interleukin (IL)-17 inhibitors (secukinumab, ixekizumab, brodalumab), an IL-12/23 inhibitor (ustekinumab), and IL-23p19 inhibitors (guselkumab, tildrakizumab, risankizumab) ...

3. www.ncbi.nlm.nih.gov › books › NBK585965Newer Biologics for the Treatment of Plaque Psoriasis

   www.ncbi.nlm.nih.gov › books › NBK585965

   1 wrz 2021 · Newer biologics such as secukinumab, ixekizumab, brodalumab and risankizumab were more favourable compared to older biologics (adalimumab, etanercept, and ustekinumab) in reaching 90% or 100% skin clearance, as measured with the Psoriasis Area Severity Index. The risk of side effects was similar between the newer and older biologics. Go to:

4. jamanetwork.com › journals › jamadermatologyComparison of Biologics and Oral Treatments for Plaque Psoriasis

   jamanetwork.com › journals › jamadermatology

   • Zapisane w pamięci cache

   In the absence of head-to-head randomized clinical trials of treatments for moderate to severe plaque psoriasis, this study provides what we believe to be a comprehensive assessment of the comparative short-term and long-term efficacy among several novel treatments.

5. www.aad.org › public › diseasesPsoriasis treatment: Biologics - American Academy of Dermatology

   www.aad.org › public › diseases

   • Zapisane w pamięci cache

   Using a biologic to treat psoriasis (or psoriatic arthritis) is life changing for some people. Biologics work by blocking reactions in your body that cause psoriasis and its symptoms. If you have psoriatic arthritis, a biologic can stop the pain, stiffness, and swelling in your joints.

6. link.springer.com › article › 10Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis...

   link.springer.com › article › 10

   • Zapisane w pamięci cache

   16 kwi 2021 · Biologics currently approved for the treatment of psoriasis include tumor necrosis factor inhibitors, interleukin (IL)-17 inhibitors, ustekinumab (an IL-12/23 inhibitor), and IL-23 inhibitors. Data from clinical trials and studies of the safety and efficacy of biologics provide essential information for the personalization of patient care.

7. onlinelibrary.wiley.com › doi › fullComparative efficacy and safety of biologics in moderate to...

   onlinelibrary.wiley.com › doi › full

   30 gru 2020 · Ixekizumab, risankizumab, and bimekizumab were among the most effective treatments, and tildrakizumab, guselkumab and risankizumab were better than the other drugs with respect to safety. Risankizumab and guselkumab performed relatively stable with respect to both efficacy and safety.